Aptevo Therapeutics Inc. AP8N.F Stock
Aptevo Therapeutics Inc. Price Chart
Aptevo Therapeutics Inc. AP8N.F Financial and Trading Overview
Aptevo Therapeutics Inc. stock price | 0.12 EUR |
Previous Close | 1.44 EUR |
Open | 1.44 EUR |
Bid | 1.44 EUR x N/A |
Ask | 1.49 EUR x N/A |
Day's Range | 1.44 - 1.44 EUR |
52 Week Range | 1.44 - 4.62 EUR |
Volume | 40 EUR |
Avg. Volume | 16 EUR |
Market Cap | 10.48M EUR |
Beta (5Y Monthly) | 5.307042 |
PE Ratio (TTM) | 0.47615892 |
EPS (TTM) | 0 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 59.5 EUR |
AP8N.F Valuation Measures
Enterprise Value | -8593460 EUR |
Trailing P/E | 0.47615892 |
Forward P/E | -0.2776062 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | Infinity |
Price/Book (mrq) | 0.44769615 |
Enterprise Value/Revenue | N/A |
Enterprise Value/EBITDA | 0.287 |
Trading Information
Aptevo Therapeutics Inc. Stock Price History
Beta (5Y Monthly) | 5.307042 |
52-Week Change | -51.40% |
S&P500 52-Week Change | 20.43% |
52 Week High | 4.62 EUR |
52 Week Low | 1.44 EUR |
50-Day Moving Average | 1.6 EUR |
200-Day Moving Average | 2.33 EUR |
AP8N.F Share Statistics
Avg. Volume (3 month) | 16 EUR |
Avg. Daily Volume (10-Days) | 0 EUR |
Shares Outstanding | 7.29M |
Float | 7.2M |
Short Ratio | N/A |
% Held by Insiders | 1.11% |
% Held by Institutions | 13.31% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor | 1:14 |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | 0% |
Gross Margin | 0% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -48.011% |
Return on Equity (ttm) | 192.44% |
Income Statement
Revenue (ttm) | 0 EUR |
Revenue Per Share (ttm) | 0 EUR |
Quarterly Revenue Growth (yoy) | N/A |
Gross Profit (ttm) | 3.11M EUR |
EBITDA | -29949000 EUR |
Net Income Avi to Common (ttm) | 16.72M EUR |
Diluted EPS (ttm) | 3.02 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 25.33M EUR |
Total Cash Per Share (mrq) | 3.47 EUR |
Total Debt (mrq) | 5.92M EUR |
Total Debt/Equity (mrq) | 25.44 EUR |
Current Ratio (mrq) | 4.914 |
Book Value Per Share (mrq) | 3.212 |
Cash Flow Statement
Operating Cash Flow (ttm) | -11339000 EUR |
Levered Free Cash Flow (ttm) | -28853250 EUR |
Profile of Aptevo Therapeutics Inc.
Country | Germany |
State | WA |
City | Seattle |
Address | 2401 4th Avenue |
ZIP | 98121 |
Phone | 206 838 0500 |
Website | https://www.aptevotherapeutics.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 45 |
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company's lead clinical candidates are APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndromes; and. ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers. Its preclinical candidates include APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40; APVO711, a dual mechanism bispecific ADAPTIR candidate designed to provide synergistic stimulation of CD40 on antigen presenting cells; and APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Q&A For Aptevo Therapeutics Inc. Stock
What is a current AP8N.F stock price?
Aptevo Therapeutics Inc. AP8N.F stock price today per share is 0.12 EUR.
How to purchase Aptevo Therapeutics Inc. stock?
You can buy AP8N.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Aptevo Therapeutics Inc.?
The stock symbol or ticker of Aptevo Therapeutics Inc. is AP8N.F.
Which industry does the Aptevo Therapeutics Inc. company belong to?
The Aptevo Therapeutics Inc. industry is Biotechnology.
How many shares does Aptevo Therapeutics Inc. have in circulation?
The max supply of Aptevo Therapeutics Inc. shares is 533.46K.
What is Aptevo Therapeutics Inc. Price to Earnings Ratio (PE Ratio)?
Aptevo Therapeutics Inc. PE Ratio is 0.00000000 now.
What was Aptevo Therapeutics Inc. earnings per share over the trailing 12 months (TTM)?
Aptevo Therapeutics Inc. EPS is 0 EUR over the trailing 12 months.
Which sector does the Aptevo Therapeutics Inc. company belong to?
The Aptevo Therapeutics Inc. sector is Healthcare.